Hepatology

A patient with decompensated liver cirrhosis treated with Namodenoson under a compassionate use program experienced improvements in disease at 20 months.

Younger age, low knowledge of HBV sequelae, and high perceived HBV stigma were linked to lower medication adherence in Korean American patients.

The analysis of NHANES data found 11.3% of adolescents have suspected MASLD. Estimates were greater for those with elevated ALT.

In patients with HCV-related compensated cirrhosis, DAA treatment was linked to lower HCC risk than no treatment but similar risk to a historical IFN cohort.

Lee explains study findings suggesting MetALD classification should be based on ≥ 3 cardiometabolic risk factors rather than just alcohol intake.

Higher Dietary Inflammatory Index scores were associated with an increased risk of developing chronic liver disease and cirrhosis progression.

GLP-1 RA use was associated with a lower risk of major cardiovascular events, clinically significant portal hypertension, and all-cause mortality in MASLD.

Exposure to aspirin and NSAIDs was linked to a reduced risk of cancer incidence and overall mortality in patients with chronic liver diseases.

GLP-1 RA use was linked to a reduced risk of alcohol-associated liver disease, lower rates of hepatic decompensation, and improved survival.

Findings suggest the value of genotyping and histological assessment for guiding HCC screening decisions in patients with chronic HBV.

Findings from the LIVERHOPE trial suggest adding simvastatin and rifaximin to standard therapy does not reduce ACLF occurrence.

Laique reviews data supporting the use of metabolic surgery in patients with obesity and cirrhotic MASH.

Laique emphasizes the unmet needs for patients with cirrhotic MASH who are not eligible for resmetirom and what role metabolic surgery may play in their care.

This month in review spotlights HCPLive’s coverage of hepatic pipeline news and recent research about MASLD, liver transplant, and alcohol in liver disease.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

Greater magnesium depletion scores were longitudinally linked to increased risks for all-cause and CVD mortality in patients with MASLD or MetALD.

Although FIB-4, ELF, and VCTE LSM performance did not vary significantly by patient characteristics, threshold adjustment was needed.

Study findings suggest NMP is especially beneficial for DCD allografts and is linked to better outcomes and resource use than SCS.

Findings suggest MASLD, especially with diabetes, overweight, or hypertension, is associated with significant fibrosis in patients with HCV.

Compared with nonsurgical treatment, metabolic surgery was associated with reduced risks of incident MALO and progression to decompensation.

Preliminary topline week 96 results showed statistically significant reversal of MASH compensated cirrhosis with efruxifermin in complete and ITT analyses.

Greater levels of physical activity and higher diet quality were linked to a reduced risk of MASLD, MetALD, and compensated advanced chronic liver disease.

The updated clinical practice guideline addresses new research and clinical developments since the first iteration of the guideline was released in 2014.

Factors associated with 30-day readmission were shorter hospital stays after transplant, insurance status, and patient history of diabetes and malignancy.

MASLD and MetALD were linked to a greater risk of incident IBD, with risk increasing as the number of associated cardiometabolic risk factors increased.